[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100544613":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":15,"centralContacts":20,"locations":28,"responsibleParty":47,"collaborators":7,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":7,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":63,"studyType":64,"phases":7,"briefSummary":65,"conditions":66,"keywords":7,"overallStatus":31,"whyStopped":7,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Azienda Ospedaliero, Universitaria Ospedali Riuniti","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":13},"DRUG","Rivaroxaban","Oral anticoagulation",[14],"Xarelto",[16],{"name":17,"affiliation":18,"role":19},"Francesco Bianco, M.D., Ph.D.","AOU - Ospedali Riuniti Ancona","PRINCIPAL_INVESTIGATOR",[21,25],{"name":17,"role":22,"phone":23,"phoneExt":7,"email":24},"CONTACT","+39 071 5965283","francesco.bianco@ospedaliriuniti.marche.it",{"name":26,"role":22,"phone":23,"phoneExt":7,"email":27},"Valentina Bucciarelli, M.D., Ph.D.","valentina.bucciarelli@ospedaliriuniti.it",[29],{"facility":30,"status":31,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"CCPC","RECRUITING","Ancona","The Marches","60123","Italy","IT",{"type":38,"coordinates":39},"Point",[40,41],13.5103,43.60717,{"lat":41,"lon":40},[44],{"name":45,"role":22,"phone":46,"phoneExt":7,"email":24},"Francesco Bianco, M.D.","+39 071 596 5316",{"type":19,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"Francesco Bianco","Principal Investigator","100544613","rivaroxaban-for-intracardiac-thrombosis-in-the-pediatric-population-100544613",false,"NCT06371170","Rivaroxaban for Intracardiac Thrombosis in the Pediatric Population","Rivaroxaban for Intracardiac Thrombosis in the Pediatric Population at Different Cardiac Sites","Inclusion Criteria:\n\n* Intracardiac thrombosis demonstration at echocardiography and CMR\u002FCCT confirmation\n* Given informed consent from the parents or tutors\n\nExclusion Criteria:\n\n* \\\u003C 38 weeks of gestational birth\n* \\\u003C 10 days of oral feeding and body weight\n* \\\u003C 2.6 Kg\n* Any major or clinically relevant bleeding event or abnormal coagulation test results within 10 days prior to the enrollment for the whole population","ALL","1 Month","16 Years",{"count":61,"type":62},20,"ESTIMATED","6 Months","OBSERVATIONAL","The goal of this observational study is to determine the efficacy of rivaroxaban treatment for intracardiac thrombi resolution in pediatric patients (\\\u003C 16 years old) diagnosed with intracardiac thrombosis. The main question it aims to answer is: Does rivaroxaban treatment resolve the thrombosis during a 3-month treatment?\n\nParticipants already taking rivaroxaban as part of their regular medical care for thrombosis resolution. They will undergo monthly visits to check that the treatment is progressing correctly and that no major bleeding has occurred. After 3 months of treatment, they will repeat the radiological imaging investigation to verify the actual resolution of the thrombosis.",[67],"Intracardiac Thrombus","2024-04-17",{"date":70,"type":71},"2024-04-19","ACTUAL",{"date":73,"type":71},"2023-01-01",{"date":75,"type":62},"2027-01-01",{"name":5,"class":6},1]